Back to Search
Start Over
A randomized controlled trial comparing two different dosages of infusional pantoprazole in peptic ulcer bleeding
- Source :
- British Journal of Clinical Pharmacology. 69:245-251
- Publication Year :
- 2010
- Publisher :
- Wiley, 2010.
-
Abstract
- WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • An adjunct to endoscopy, proton pump inhibitor (PPI) is effective pharmacotherapy in high-risk patients with peptic ulcer bleeding (PUB). • An intravenous 80-mg bolus and 192 mg day−1 successive infusion for 3 days is the currently recommended dosing modality in administering PPI. WHAT THIS STUDY ADDS • Clinical outcomes are not different in PUB patients receiving infusional pantoprazole at either 192 mg or 160 mg day−1 for 3 days. • The effective dosage of PPI may not be as high as currently recommended. • In view of cost-effectiveness, a lower dosage (160 mg day−1) of infusional PPI may be adopted in the management of PUB. AIM The optimal dosage of proton pump inhibitor in bleeding peptic ulcers remains controversial. The aim was to compare the clinical effectiveness of two doses of infusional pantoprazole in peptic ulcer bleeding. METHODS Peptic ulcer patients (n= 120) with bleeding stigmata were enrolled after successful endoscopic therapy. After an initial bolus injection of 80 mg pantoprazole, patients were randomized to receive continuously infused pantoprazole at either 192 mg day−1 or 40 mg every 6 h (i.e. 160 mg day−1) for 3 days. Clinical outcomes between the two groups within 14 days were compared, with 14-day recurrent bleeding regarded as the primary end-point. RESULTS Both groups (n= 60 each) were well matched in demographic and clinical factors upon entry. Bleeding totally recurred in 11 (9.2%) patients, with six (10%) in the 192 mg day−1 group and five (8.3%) in the 160 mg day−1 group (relative risk of bleeding recurrence between two treatments 1.2; 95% CI 0.39, 3.72). All secondary outcomes between the two groups were similar, including the amount of blood transfusion (mean 1179 ml vs. 1203 ml, P > 0.1), hospital stay (mean 9.5 days vs. 9.9 days, P > 0.1), need for surgery (n= 1 vs. n= 0, P > 0.1), and mortality (n= 1 vs. n= 0, P > 0.1). CONCLUSIONS Following endoscopic haemostasis, infusional pantoprazole at either 192 mg day−1 or 40 mg every 6 h appear similar.
- Subjects :
- Male
medicine.medical_specialty
medicine.drug_class
Peptic
Proton-pump inhibitor
Peptic Ulcer Hemorrhage
Gastroenterology
2-Pyridinylmethylsulfinylbenzimidazoles
law.invention
Pharmacotherapy
Bolus (medicine)
Randomized controlled trial
Recurrence
law
Internal medicine
medicine
Humans
Pharmacology (medical)
Dosing
Infusions, Intravenous
Pantoprazole
Pharmacology
business.industry
Proton Pump Inhibitors
Anti-Ulcer Agents
Miscellaneous
Surgery
Treatment Outcome
Female
business
medicine.drug
Subjects
Details
- ISSN :
- 13652125 and 03065251
- Volume :
- 69
- Database :
- OpenAIRE
- Journal :
- British Journal of Clinical Pharmacology
- Accession number :
- edsair.doi.dedup.....fed55e9c61ededd41472715c8602b6df
- Full Text :
- https://doi.org/10.1111/j.1365-2125.2009.03575.x